These findings are further supported by the results of a study that demonstrated remarkable concordance between blood and tumor samples for determining rat sarcoma (RAS) status and BRAF mutations, especially in patients with CLM [52,53,54,55]. This evidence concerns the gene BRAF and neoplasm.